The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

[1]  M. Malim,et al.  Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.

[2]  P. Moss,et al.  Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1 , 2021, SSRN Electronic Journal.

[3]  Gregory F. Wu,et al.  Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, medRxiv.

[4]  D. Bonsall,et al.  Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial , 2021, The Lancet.

[5]  C. Lees,et al.  Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD , 2021, Gut.

[6]  P. Klenerman,et al.  T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study , 2021, SSRN Electronic Journal.

[7]  K. Cadwell,et al.  Serological response to COVID-19 vaccination in IBD patients receiving biologics , 2021, medRxiv.

[8]  D. Segev,et al.  Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. , 2021, JAMA.

[9]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[10]  A. Iafrate,et al.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[11]  D. Stuart,et al.  Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera , 2021, Cell.

[12]  L. Trupin,et al.  Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2021, Annals of the Rheumatic Diseases.

[13]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[14]  F. Underwood,et al.  Effect of IBD medications on COVID-19 outcomes: results from an international registry , 2020, Gut.

[15]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.

[16]  Matthew S. Miller,et al.  Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.

[17]  R. Cox,et al.  Not just antibodies: B cells and T cells mediate immunity to COVID-19 , 2020, Nature Reviews Immunology.

[18]  M. Wurfel,et al.  A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections , 2020, The Journal of Immunology.

[19]  K. Bhaskaran,et al.  Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.

[20]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[21]  G. Koh,et al.  Faculty Opinions recommendation of Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[22]  R. Giesey,et al.  The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017. , 2020, Journal of the American Academy of Dermatology.

[23]  P. Hotez,et al.  The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement , 2020, Microbes and Infection.

[24]  T. H. Nguyen,et al.  The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.

[25]  G. Collins,et al.  Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017 , 2019, Annals of the rheumatic diseases.

[26]  R. Emsley,et al.  Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) , 2019, British Journal of Dermatology.

[27]  N. Reynolds,et al.  Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) , 2018, British Journal of Dermatology.

[28]  E. Lee,et al.  Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial , 2018, Annals of the rheumatic diseases.

[29]  S. H. van der Burg,et al.  Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections , 2018, Front. Immunol..

[30]  M. Lebwohl,et al.  Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, JAMA dermatology.

[31]  E. Bonfá,et al.  Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice , 2011, Annals of the rheumatic diseases.

[32]  L. Bloom,et al.  IL-21 Receptor Is Critical for the Development of Memory B Cell Responses , 2011, The Journal of Immunology.

[33]  C. Ewen,et al.  Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. , 2009, Vaccine.